Of @ treated patients in the phase III trial , @ % had mild renal impairment ( creatinine clearance > @ to @ mL/min ; n = @ for nab-P/C and n = @ for sb-P/C ) and @ % had moderate renal impairment ( creatinine clearance @ mL/min : n = @ for nab-P/C and n = @ for sb-P/C ) .